N J Meropol

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

Margaret von Mehren, Philip M. Arlen, James L. Gulley et al. · PubMed · 2001 · 170 citations

Immunology, Pathology, Immunotherapeutics +18

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200

Bruce J. Giantonio, David T. Levy, P J O’Dwyer et al. · Annals of Oncology · 2006 · 135 citations · Full text

Medicine, Pharmacology, Colorectal Cancer +9

Severed Myelosuppression Resulting From Concurrent Administration of Granulocyte Colony-Stimulating Factor and Cytotoxic Chemotherapy

N J Meropol, Langdon L. Miller, Edward L. Korn et al. · JNCI Journal of the National Cancer Institute · 1992 · 101 citations

Immunology, Pathology, Metronomic Chemotherapy +17

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing

Todd A. Fehniger, James M. Hitt, Michael A. Caligiuri et al. · Cancer Immunology Immunotherapy · 1998 · 82 citations · Full text

Inflammation, Cell Therapy, Immunology +8

Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.

N J Meropol, Michelle M. Porter, Leslie E. Blumenson et al. · PubMed · 1996 · 70 citations

Immunology, Nk Cells, Immunoediting +19